APTA.LSE Aptamer Group PLC
- Market cap
- GBX 9.45M
- P/E
- -
- P/B
- 1.78x
- ROE
- -32.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is APTA.LSE undervalued?
Graham numberThe Graham number of Aptamer Group PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aptamer Group PLC fundamental analysis
No fundamental analysis for Aptamer Group PLC yet.
Aptamer Group PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aptamer Group PLC
Aptamer Group PLC, together with its subsidiaries, provides synthetic binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, the United States, and internationally. The company offers Optimer, a platform that enables the discovery and development of optimized DNA and RNA aptamers, which can bind to target molecules. Its platform is used in research reagent and analytical, bioprocessing, diagnostic, cosmetic and consumer health, and therape…
Full company profileAptamer Group PLC financial statements
Aptamer Group PLC annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 987K | 855K | 1.28M | 4.04M | 1.75M | 860K | 1.20M | 1.54M |
| Gross Profit | 613K | 456K | 538K | 2.69M | 359K | 250K | 350K | 573K |
| Operating Income | -540K | -922K | -2.30M | -2.58M | -8.16M | -3.08M | -2.70M | -2.85M |
| EBITDA | -425K | -734K | -2.04M | -2.20M | -7.36M | -2.82M | -2.28M | -2.60M |
| Net Income | -455K | -675K | -1.85M | -2.09M | -7.84M | -2.96M | -2.42M | -1.86M |
| EPS | -0.01 | -0.01 | -0.03 | -0.03 | -0.11 | -0.01 | 0.00 | 0.00 |
| Balance Sheet | ||||||||
| Total Assets | 1.40M | 1.39M | 2.06M | 11.5M | 2.75M | 2.77M | 2.83M | 7.18M |
| Total Liabilities | 497K | 1.14M | 1.96M | 3.47M | 2.45M | 1.88M | 1.45M | 1.44M |
| Shareholders' Equity | 900K | 246K | 105K | 8.05M | 304K | 887K | 1.38M | 5.74M |
| Cash & Short-term Investments | 727K | 293K | 369K | 6.69M | 234K | 870K | 1.06M | 4.36M |
| Total Debt | 71.6K | 161K | 78.0K | 1.31M | 1.08M | 817K | 491K | 170K |
| Cash Flow | ||||||||
| Operating Cash Flow | -845K | -82.7K | -1.10M | -2.38M | -4.06M | -2.28M | -2.00M | -2.13M |
| Capital Expenditure | 40.8K | 161K | 158K | 418K | 2.03M | 122K | 10.0K | 172K |
| Free Cash Flow | -886K | -244K | -1.26M | -2.79M | -6.09M | -2.41M | -2.01M | -2.30M |
| Ratios | ||||||||
| ROE | -50.6% | -274.5% | -1,761.5% | -26.0% | -2,577.6% | -333.5% | -175.4% | -32.5% |
| ROA | -32.6% | -48.5% | -89.6% | -18.2% | -284.6% | -106.8% | -85.5% | -25.9% |
| Net Profit Margin | -46.1% | -79.0% | -144.5% | -51.9% | -447.3% | -344.0% | -201.5% | -120.6% |
| Debt to Equity | 0.08x | 0.65x | 0.74x | 0.16x | 3.55x | 0.92x | 0.36x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aptamer Group PLC dividends
Aptamer Group PLC has not paid dividends in the last 8 fiscal years.
Who owns Aptamer Group PLC
- Insiders 24.43%
- Institutions 9.52%
- Public & others 66.05%
- Shares outstanding 3.47B
- Free float 2.84B
Aptamer Group PLC company profile
- Company name
- Aptamer Group PLC
- Ticker
- APTA.LSE
- ISIN
- GB00BNRRP542
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 34
- Fiscal year end
- March
- Address
- Windmill House, York, United Kingdom, YO10 5BR
- Phone
- 44 19 0421 7404
- Website
- aptamergroup.com
About Aptamer Group PLC
Aptamer Group PLC, together with its subsidiaries, provides synthetic binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, the United States, and internationally. The company offers Optimer, a platform that enables the discovery and development of optimized DNA and RNA aptamers, which can bind to target molecules. Its platform is used in research reagent and analytical, bioprocessing, diagnostic, cosmetic and consumer health, and therapeutic applications. The company serves pharmaceutical, diagnostic, and bioprocessing companies. It has collaborations with Unilever, Neuro-Bio, the University of Glasgow, AstraZeneca, and Invizius. Aptamer Group PLC was founded in 2008 and is headquartered in York, the United Kingdom.
Aptamer Group PLC management
3- Dr. Arron Craig TolleyCEO, Co-Founder & Director · born 1977
- Mr. Andrew Mark RapsonCFO, Company Secretary & Director · born 1981
- Dr. David BunkaChief Scientific Officer & Executive Director · born 1978